BIARYLMETAPYRIMIDINKINASEINHIBITOREN

European patent · EP1951684 · Deleted

Register entry

Publication number: EP1951684
Application number: EP06836583
Kind: European patent with effect for Switzerland and Liechtenstein
Status: Deleted
Specification: Granted
Filed: Oct 26, 2006
Published: Aug 6, 2008
Granted: Jul 13, 2016
Deleted: Oct 26, 2026
Reason: Maximum term reached
IPC classes: A61P 35/00 (2006.01)
Priority: US 732629 P 01.11.2005
US 838003 P 15.08.2006
PCT application: PCT/US2006/042044 26.10.2006
PCT publication: WO2007/053452 10.05.2007
Filing language: English
Source: Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Fedratinib

C01951684/01 · Medicine · Granted · Protection from Oct 26, 2026 to Oct 25, 2031

Authorisation 67792 (Swissmedic, Jul 1, 2021)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

Oct 26, 2026
Maximum term reached
Status of protective title
Active → Cancelled
Cancellation date
26.10.2026
Cause for cancellation
Expiry of maximum term of protection
Published in Swissreg on 26.10.2026
Feb 10, 2026
Holder’s address changed
Owner
IMPACT BIOMEDICINES, INC., 86 Morris Avenue, Summit, New Jersey 07901, USA → IMPACT BIOMEDICINES, INC., Route 206 and Province Line Road, Princeton, New Jersey 08543, USA
Published in Swissreg on 10.02.2026
Nov 1, 2025
Next annual fee due on
Next annual fee due on
31.10.2025 → 31.10.2026
Published in Swissreg on 01.11.2025
Nov 1, 2024
Next annual fee due on
Next annual fee due on
31.10.2024 → 31.10.2025
Published in Swissreg on 01.11.2024
Dec 21, 2023
Address changed
Representative
E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich → E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich
Published in Swissreg on 21.12.2023
Nov 1, 2023
Change
Published in Swissreg on 01.11.2023
Nov 1, 2022
Change
Published in Swissreg on 01.11.2022
Aug 6, 2021
Agent entered
Representative
E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich
Published in Swissreg on 06.08.2021

4 earlier entries

Jul 6, 2019
Address changed
Owner
IMPACT BIOMEDICINES, INC., 12526 High Bluff Drive, Suite 260, San Diego, California 92130, USA → IMPACT BIOMEDICINES, INC., 86 Morris Avenue, Summit, New Jersey 07901, USA
Published in Swissreg on 06.07.2019
Jul 5, 2019
Transferred
Owner
TargeGen, Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA → IMPACT Theraupeutics, Inc., 12526 High Bluff Drive, Suite 260, San Diego, California 92130, USA
Published in Swissreg on 05.07.2019
Jul 5, 2019
Address changed
Owner
IMPACT Theraupeutics, Inc., 12526 High Bluff Drive, Suite 260, San Diego, California 92130, USA → IMPACT BIOMEDICINES, INC., 12526 High Bluff Drive, Suite 260, San Diego, California 92130, USA
Published in Swissreg on 05.07.2019
Jul 13, 2016
Granted
Published in Swissreg on 13.07.2016

Parties

Holder

Impact Biomedicines, Inc.

IMPACT BIOMEDICINES, INC.

Route 206 and Province Line Road, Princeton, New Jersey 08543, US

Agent

E. Blum & Co. AG

Hofwiesenstrasse 349, 8050 Zürich

Inventor

CAO, Jianguo

San Diego, CA 92128-2077, US

HOOD, John

San Diego, CA 92130, US

LOHSE, Daniel

San Diego, CA 92122, US

MAK, Chi, Ching

San Diego, CA 92128, US

MC PHERSON, Andrew

San Diego, CA 92129, US

NORONHA, Glenn

Oceanside, CA 92057, US

PATHAK, Ved

San Diego, CA 92130, US

RENICK, Joel

San Diego, CA 92115, US

SOLL, Richard, M.

San Diego, CA 92130, US

ZENG, Binqi

San Diego, CA 92129, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.